As covid-19 drug Lianhua Qingwen product was involved in the storm of questioning the efficacy, the share price of Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) ( Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) . SZ) fell by the limit on the morning of April 18, which was another limit after April 15.
Lianhua Qingwen capsule (granule) is the leading product of Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) and is mainly used for the treatment of cold and influenza related diseases. In April 12, 2020, the State Drug Administration approved Lianhua Qingwen capsules (granules) on the basis of the original approved indications to increase the new indications of "New Coronavirus pneumonia with light and ordinary type".
In the first three quarters of 2021, Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) Lianhua Qingwen products achieved an operating revenue of 3.37 billion yuan, accounting for 41.6% of the company's total operating revenue.
Looking back on the covid-19 epidemic, traditional Chinese medicine has been used in epidemic prevention and control for many times. For example, at the press conference on epidemic prevention and control in Shanghai on April 5, Fang min, President of Shuguang Hospital Affiliated to Shanghai University of traditional Chinese medicine and head of the epidemic prevention and control base of traditional Chinese medicine, said that traditional Chinese medicine played a positive role in covid-19 epidemic prevention and control. For those with positive infection in Shanghai, the utilization rate of traditional Chinese medicine remained stable at more than 98%. Shanghai Municipal TCM expert group and designated hospitals carried out clinical diagnosis and treatment in accordance with the ninth edition of the diagnosis and treatment plan, combined with the syndrome differentiation characteristics of Shanghai style TCM, and achieved good results. Preliminary clinical data show that it has unique advantages in accelerating discharge rate and blocking progress.
On April 15, Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) responded to the doubts of the market on the investor interaction platform.
Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) said that Lianhua Qingwen is an innovative patented traditional Chinese medicine developed under the guidance of collateral disease theory. Lianhua Qingwen has been included in the New Coronavirus pneumonia diagnosis and treatment plan jointly issued by the National Health Protection Commission and the State Administration of traditional Chinese medicine (Trial fourth / five / six / seven / eight / nine Edition) and the diagnosis and treatment plan of COVID-19 pneumonia in more than 20 provinces and cities.
Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) said that Lianhua Qingwen has gathered three famous prescriptions of traditional Chinese medicine in the fight against epidemic diseases for 2000 years, and added drugs that aromatize dampness, protect the spleen and stomach, improve immunity and strengthen Qi. It has multiple effects of broad-spectrum antiviral, bacteriostatic and anti-inflammatory, effectively prevent and treat lung infection and improve body immunity. Lianhua Qingwen was developed in the 2003 epidemic prevention and control period in SARS, and played an important role in the prevention and control of influenza A in 2009. Since 2020, it has made significant contributions to the prevention and control of COVID-19 pneumonia.
Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) said that a number of authoritative scientific research institutions in China have carried out a series of basic and clinical studies on Lianhua Qingwen's anti covid-19 pneumonia, forming a chain of evidence of "cell animal preventive drug clinical treatment" for the prevention and treatment of covid-19 pneumonia. Experiments have confirmed that the drug has a significant inhibitory effect on the original strain of covid-19 virus and its variant strains Delta and Omicron. At present, 35 papers on experimental and clinical research have been published (15 published abroad), among which Lianhua Qingwen capsule is effective and safe in preventing New Coronavirus pneumonia: prospective open label controlled trial. The real world research paper was published in the International Journal Evidence-Based Complementary and Alternative Medicine. The results showed that the nucleic acid detection positive rate of Lianhua Qingwen intervention group was 0.27%, which was significantly lower than that of the control group (1.14%). The prevention of Lianhua Qingwen in close contact population could reduce the positive infection rate of covid-19 pneumonia by 76%, and the safety was good.
"At present, the company is going all out to do a good job in scientific research, ensure quality and quantity production, ensure market supply and contribute to epidemic prevention and control. We call on everyone to work together to fight the epidemic, overcome difficulties and rationally identify the untrue remarks on Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) and Lianhua Qingwen on the Internet." Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) said so
Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) response to query: the study on Lianhua Qingwen preventing covid-19 pneumonia has been published
